The Department of Health and Human Services (HHS) announced a $290 million purchase of the drug Nplate from Amgen to treat blood cell injuries caused by radiological or nuclear emergencies. While officials claim the procurement is part of a long-planned preparedness strategy, skeptics suggest the timing is suspicious given current geopolitical tensions. The move is characterized by some as a financial payout to a pharmaceutical company that did not profit from the COVID-19 vaccine market.
